<table-wrap xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" id="tbl5" position="float"><object-id pub-id-type="doi">10.7554/eLife.22889.028</object-id><label>Table 5.</label><caption><p>Top 5 PD-1 residues contributing to desolvation energy when binding to PD-L1 and pembrolizumab. Binding energies were calculated using the FastContact web server (<xref ref-type="bibr" rid="bib4">Champ and Camacho, 2007</xref>) and cocrystal structures of PD-1 bound to PD-L1 (<xref ref-type="bibr" rid="bib45">Zak et al., 2015</xref>) and pembrolizumab (<xref ref-type="bibr" rid="bib17">Horita et al., 2016</xref>).</p><p><bold>DOI:</bold> <ext-link ext-link-type="doi" xlink:href="10.7554/eLife.22889.028">http://dx.doi.org/10.7554/eLife.22889.028</ext-link></p></caption><table frame="hsides" rules="groups"><thead><tr><th colspan="2" valign="top">PD-L1&#8211;bound</th><th colspan="2" valign="top">Pembrolizumab&#8211;bound</th></tr><tr><th valign="top">Residue</th><th valign="top">Energy (kcal/mol)</th><th valign="top">Residue</th><th valign="top">Energy (kcal/mol)</th></tr></thead><tbody><tr><td valign="bottom">Ile126<sup>*</sup></td><td valign="bottom">&#8722;1.853</td><td valign="bottom">Leu128<sup>&#8224;</sup></td><td valign="bottom">&#8722;2.886</td></tr><tr><td valign="bottom">Leu128<sup>&#8224;</sup></td><td valign="bottom">&#8722;1.673</td><td valign="bottom">Pro89</td><td valign="bottom">&#8722;2.486</td></tr><tr><td valign="bottom">Ile134<sup>&#8225;</sup></td><td valign="bottom">&#8722;1.361</td><td valign="bottom">Val64</td><td valign="bottom">&#8722;1.721</td></tr><tr><td valign="bottom">Val64</td><td valign="bottom">&#8722;0.463</td><td valign="bottom">Pro130</td><td valign="bottom">&#8722;1.586</td></tr><tr><td valign="bottom">Ala132</td><td valign="bottom">&#8722;0.37</td><td valign="bottom">Pro83</td><td valign="bottom">&#8722;1.131</td></tr></tbody></table><table-wrap-foot><fn id="tblfn4"><p><sup>*</sup>The I126A mutation greatly reduces binding of PD-1 to both PD-L1 and PD-L2 (<xref ref-type="bibr" rid="bib22">L&#225;z&#225;r-Moln&#225;r et al., 2008</xref>).</p></fn><fn id="tblfn5"><p><sup>&#8224;</sup>The L128A mutation abolishes binding of PD-1 to PD-L1 and partially reduces binding to PD-L2 (<xref ref-type="bibr" rid="bib22">L&#225;z&#225;r-Moln&#225;r et al., 2008</xref>).</p></fn><fn id="tblfn6"><p><sup>&#8225;</sup>The I134A mutation abolishes binding of PD-1 t oPD-L1 and greatly reduces binding to PD-L2 (<xref ref-type="bibr" rid="bib22">L&#225;z&#225;r-Moln&#225;r et al., 2008</xref>).</p></fn></table-wrap-foot></table-wrap>